Cancer Genetics Inc (NASDAQ:VYNT) is moving up in pre-open session after announcing quarterly results. The stock was up higher in pre-market trading, but has settled back a bit. The fact it traded above yesterday’s close could hint a bounce may be in the cards.
As of 8:05, VYNT stock surged 4.17% to $3.50. So far more than 12K shares have exchanged hands.
VYNT Reports First Quarter 2021 Results
Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update
- Total revenues increased 32%, or $54 thousand, to $222 thousand for the three months ended March 31, 2021, as compared with $168 thousand for the three months ended March 31, 2020.
- Research and development expenses decreased by 19%, or $189 thousand to $820 thousand for the three months ended March 31, 2021 from $1.0 million for the three months ended March 31, 2020.
- Cost of goods sold – service aggregated $89 thousand and $132 thousand, respectively, for the three months ended March 31, 2021 and 2020, resulting in a cost of goods sold of 77% and 97%, respectively, of service revenues.
|SHARES OUTSTANDING||28.98 M|
|SHARE FLOAT (%)||24.68 M (85.15%)|
|% HELD BY INSTITUTIONS||2.14|
Recent Stock Performance
|+/- EMA(20)||3.48 (-3.45%)|
|+/- SMA(50)||4.43 (-24.15%)|
|+/- SMA(200)||3.97 (-15.37%)|
|CCI20||-71.3152||Sell||Chaikin Money Flow||-0.1565||Sell|
|MACD||-0.0840||Sell||Money Flow Index||68.2670||Sell|
|STOCH (14,3)||32.6923||Neutral||STOCH RSI||0.9749||OverBought|